Peter Harwin resigned as Director at Spyre Therapeutics, Inc..
“In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.”
Spyre Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Spyre Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Spyre Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Spyre Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $463.5 million (effective 2026-04-14).
“The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions.”
Spyre Therapeutics, Inc. reported preliminary financial results for the quarter ended March 31, 2026.
“the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.